TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System.

ABSTRACT: TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment. This longitudinal descriptive study aimed at assessing infliximab, etanercept and adalimumab biosimilar penetration rates using data of the French National Health Data System. A total of 207,118 new or prevalent users from the date of first biosimilar commercialization in France (respectively January 2015, May 2016 and October 2018) were included in the study and followed until September 30, 2021. Biosimilars represented respectively 78%, 46% and 53% of the overall initiations, and 94%, 66% and 60% last year's initiations. A total of 46%, 19% and 17% of originator product preva

SUBMITTER: Jourdain H 

PROVIDER: S-EPMC9666557 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature